表紙:淋病 (感染症):開発中の薬剤、2021年
市場調査レポート
商品コード
1017643

淋病 (感染症):開発中の薬剤、2021年

Gonorrhea (Infectious Disease) - Drugs In Development, 2021

出版日: | 発行: Global Markets Direct | ページ情報: 英文 127 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.12円
淋病 (感染症):開発中の薬剤、2021年
出版日: 2021年06月30日
発行: Global Markets Direct
ページ情報: 英文 127 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

淋病は、淋菌によって引き起こされる性感染症 (STD) です。男性と女性の両方に感染する可能性があります。細菌は、尿道・膣・子宮頸部・子宮内膜の表面や、まぶたの裏打ち、喉、卵管などの粘膜の細胞を標的とします。主な症状には、排尿時の疼痛や、陰茎からの膿のような分泌物、膣分泌物の増加、腹痛、骨盤痛などがあります。主な治療法には抗生物質などが含まれます。

当レポートでは、世界各国での淋病治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

目次

  • イントロダクション
  • 淋病:概要
  • 淋病:治療薬の開発
  • 淋病:治療薬の評価
  • 淋病:治療薬の開発に従事している企業
  • 淋病:薬物プロファイル
  • 淋病:開発が休止状態のプロジェクト
  • 淋病:開発が中止された製品
  • 淋病:製品開発のマイルストーン
  • 付録
図表

List of Tables

List of Tables

  • Number of Products under Development for Gonorrhea, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Gonorrhea - Pipeline by Biolytics Pharma, 2021
  • Gonorrhea - Pipeline by Boulos and Cooper Pharmaceuticals Pty Ltd, 2021
  • Gonorrhea - Pipeline by Nabriva Therapeutics Plc, 2021
  • Gonorrhea - Pipeline by Paratek Pharmaceuticals Inc, 2021
  • Gonorrhea - Pipeline by Pharmiva AB, 2021
  • Gonorrhea - Pipeline by Redx Pharma Plc, 2021
  • Gonorrhea - Pipeline by TherapyX Inc, 2021
  • Gonorrhea - Pipeline by Yaso Therapeutics Inc, 2021
  • Gonorrhea - Dormant Projects, 2021
  • Gonorrhea - Discontinued Products, 2021

List of Figures

List of Figures

  • Number of Products under Development for Gonorrhea, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021
目次
Product Code: GMDHC12845IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gonorrhea (Infectious Disease) - Drugs In Development, 2021, provides an overview of the Gonorrhea (Infectious Disease) pipeline landscape.

Gonorrhea is a sexually transmitted disease (STD) caused by Neisseria gonorrhoeae bacterium. It can infect both males and females. The bacteria target the cells of the mucous membranes including surfaces of the urethra, vagina, cervix and endometrium, lining of the eyelid, the throat and fallopian tubes. Symptoms include painful urination, pus-like discharge from penis, increased vaginal discharge, abdominal pain and pelvic pain. Treatment includes antibiotics.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gonorrhea (Infectious Disease) - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Gonorrhea (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gonorrhea (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Gonorrhea and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Preclinical, Discovery and Unknown stages are 3, 11, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 3 molecules, respectively.

Gonorrhea (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Gonorrhea (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Gonorrhea (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Gonorrhea (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Gonorrhea (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Gonorrhea (Infectious Disease)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Gonorrhea (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Gonorrhea (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

  • Introduction
  • Gonorrhea - Overview
  • Gonorrhea - Therapeutics Development
  • Gonorrhea - Therapeutics Assessment
  • Gonorrhea - Companies Involved in Therapeutics Development
  • Gonorrhea - Drug Profiles
  • Gonorrhea - Dormant Projects
  • Gonorrhea - Discontinued Products
  • Gonorrhea - Product Development Milestones
  • Appendix